Home > Search Clinical Trials > Cancer - Lung

IRB No. U26-053-2 (Dr. Nathaniel Robinson, PI): A Phase III, Randomized, Double-Blind, Multicenter; Global Study of Rilvegostomig or Pembrolizumab Monotherapy for the First-line Treatment of Patients with PD-L1-high Metastatic Non-small cell Lung Cancer (ARTEMIDE-Lung04)

The purpose of this study is to learn more about the effectiveness and safety of the study drug rilvegostomig (also called AZD2936) compared to pembrolizumab (also called KEYTRUDA), a standard treatment option for metastatic NSCLC.

IRB No. U26-070-1 (Dr. Nathaniel Robinson, PI): A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084 in Combination With Subcutaneous Pembrolizumab and Berahyaluronidase alfa (MK-3475A) Versus MK-3475A in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Chemotherapy as First-line Treatment of Participants With KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC (KANDLELIT-007)

This trial is testing MK 1084, an experimental drug, given with MK 3475A, an experimental combination and administration of drugs, in people who have nonsquamous non-small cell lung cancer (NSCLC)